This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on june 17, 2016.Upon further investigation of the reported event, the following information is new and/or changed.(b)(4).The actual device was returned for evaluation.Review of the device history records revealed no manufacturing issues.The returned sample was visually inspected.Visual inspection of the returned sample confirmed the presence of excess bonding agent on the tubing around the port of the venous line on the venous inlet.No damages were present in the affected area of the product.The cause of the event is excess bonding agent on the tubing when it is inserted into the port, causing the bonding agent to be pushed down the outside of the tubing by the port.The bonding agent then dries on the outside of the tubing allowing it to be visible by the customer.This is not a functional issue, but is rather a cosmetic issue only.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|